Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic acid for prevention of skeletal events in breast cancer patients with osteoporosis
2010-019216-20Phase 2Active
- Sponsor
- Azienda Ospedaliero Universitaria di Cagliari
- Start
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of zoledronic acid in osteoporosis and breast cancer, sponsored by Azienda Ospedaliero Universitaria di Cagliari. Primary endpoint: Change in bone mineral density. Started Apr 2010; status: active.
02
Drugs
zoledronic acid
03
Conditions
osteoporosisbreast cancer
Beyond the preview
Go deeper on 2010-019216-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019216-20.